natgillin/translations-raw huggingface dataset:
The most common side effects with Leucofeligen FeLV/RCP (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (<2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances. 
Najpogostejši neželeni učinki zdravila Leucofeligen FeLV/RCP (ki lahko prizadenejo največ 1 mačko od 10) so zmerna in kratkotrajna lokalna reakcija (< 2 cm) po prvi injekciji, ki običajno izzveni v treh ali štirih tednih brez zdravljenja, povišana telesna temperatura (ki traja od enega do štirih dni), apatija (ravnodušnost) in prebavne motnje.
Because Leucofeligen FeLV/RCP is made up of two vaccines that have been available in the European Union (EU) since the 1980s (Feligen RCP and Leucogen), the company used data from studies carried out with these vaccines to support the use of Leucofeligen FeLV/RCP. 
Ker je zdravilo Leucofeligen FeLV/RCP narejeno iz dveh cepiv, ki sta v Evropski uniji (EU) na voljo od osemdesetih let dvajsetega stoletja (Feligen RCP in Leucogen) je podjetje v podporo uporabi zdravila Leucofeligen FeLV/RCP uporabilo podatke iz študij, opravljenih s tema dvema cepivoma.
A laboratory study in which cats were exposed to feline leukaemia virus confirmed that following the first annual booster vaccination cats were protected for a three year period against leukaemia. 
Laboratorijska študija, v kateri so bile mačke izpostavljene virusu mačje levkemije, je potrdila, da so te po prvem letnem obnovitvenem cepljenju pred levkemijo zaščitene tri leta.
It also contains a protein of feline leukaemia virus (FeLV). 
Vsebuje tudi beljakovino virusa mačje levkemije (FeLV).
Leucofeligen FeLV/RCP contains small amounts of the three weakened viruses as listed above and a protein from the outer layer of FeLV called ‘envelope p45 protein'. 
Zdravilo Leucofeligen FeLV/RCP vsebuje majhne količine treh vrst oslabljenih virusov, ki so našteti zgoraj, in beljakovino iz zunanje ovojnice FeLV, imenovano „beljakovina ovojnice p45“.
In addition, it reduced the excretion of feline viral rhinotracheitis viruses, prevented a fall in white blood cell counts in feline panleucopenia and prevented FeLV from remaining in the blood. 
Poleg tega je zmanjšalo izločanje mačjih virusnih rinotraheitis virusov, preprečilo padec ravni belih krvnih celic pri panlevkopeniji mačk in preprečilo ostajanje FeLV v krvi.
The vaccine contains live feline viruses that have been attenuated (weakened) so they do not cause disease: feline calicivirus (strain F9), viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72). 
Virus vsebuje žive mačje viruse, ki so bili atenuirani (oslabljeni) in tako ne povzročajo bolezni: mačji kalicivirus (sev F9), virus virusnega rinotraheitisa (sev F2) in virus mačje panlevkopenije (sev LR 72).
For more information about using Leucofeligen FeLV/RCP, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Leucofeligen FeLV/RCP glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
The studies showed that Leucofeligen FeLV/RCP provided protection against the diseases listed above as measured by the presence of antibodies against the viruses in the vaccinated kittens' blood. 
Študije so pokazale, da je zdravilo Leucofeligen FeLV/RCP zagotovilo zaščito pred zgoraj naštetimi boleznimi, pri čemer je bilo merilo prisotnost protiteles proti virusom v krvi cepljenih mladičev.
Leucofeligen FeLV/RCP has been examined in two main ‘field' studies involving kittens aged eight to nine weeks. 
Zdravilo Leucofeligen FeLV/RCP je bilo proučeno v dveh glavnih študijah na terenu z mačjimi mladiči, starimi od osem do devet tednov.
When a cat is given the vaccine, the immune system recognises the weakened viruses and the FeLV proteins as ‘foreign' and makes antibodies against them. 
Ko mačko cepimo, imunski sistem prepozna oslabljene viruse in beljakovine virusa FeLV kot tujek ter proti njim razvije protitelesa.
The vaccine starts to protect against panleucopenia and leukaemia 3 weeks after the second injection and protection against calicivirosis and viral rhinotracheitis starts 4 weeks after the second injection. 
Cepivo začne ščititi pred panlevkopenijo in levkemijo tri tedne po drugem injiciranju, pred kalicivirozo in virusnim rinotraheitisom pa štiri tedne po drugem injiciranju.
Leucofeligen FeLV/RCP is available as two vials, one containing a white powder pellet and one containing a liquid. 
Zdravilo Leucofeligen FeLV/RCP je na voljo v obliki dveh vial, od katerih ena vsebuje bele pelete, druga pa tekočino.
Leucofeligen FeLV/RCP is a vaccine. 
Zdravilo Leucofeligen FeLV/RCP je cepivo.
Leucofeligen FeLV/RCP should not be used in pregnant cats. 
Zdravilo Leucofeligen FeLV/RCP se ne sme uporabljati pri brejih mačkah.
Other information about Leucofeligen FeLV/RCP 
Druge informacije o zdravilu Leucofeligen FeLV/RCP
For the full list of side effects and restrictions with Leucofeligen FeLV/RCP, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev zdravila Leucofeligen FeLV/RCP glejte navodilo za uporabo.
An overview of Leucofeligen FeLV/RCP and why it is authorised in the EU 
Pregled zdravila Leucofeligen FeLV/RCP in zakaj je odobreno v EU
Why is Leucofeligen FeLV/RCP authorised in the EU? 
Zakaj je bilo zdravilo Leucofeligen FeLV/RCP odobreno v EU?
It also prevents feline panleucopenia and persistent viraemia for feline leukaemia (the presence of feline leukaemia virus in the blood). 
Preprečuje tudi panlevkopenijo mačk in trajno viremijo pri levkemiji mačk (prisotnost virusa levkemije mačk v krvi).
What is Leucofeligen FeLV/RCP and what is it used for? 
Kaj je zdravilo Leucofeligen FeLV/RCP in za kaj se uporablja?
In the future, the cat's immune system will be able to produce antibodies more quickly when it is exposed to the disease-causing forms of the viruses. 
Ob ponovni izpostavitvi oblikam virusov, ki povzročajo bolezni, bo lahko imunski sistem mačke hitreje tvoril protitelesa.
FeLV/RCP only every 3 years, with annual revaccination in intervening years with the vaccine Feligen RCP to protect against calicivirosis, rhinotracheitis and panleucopenia. 
Zato starejše mačke potrebujejo ponovno cepljenje z zdravilom Leucofeligen FeLV/RCP samo vsaka tri leta ter ponovno cepljenje z zdravilom Feligen RCP vsako leto v vmesnih letih za zaščito pred kalicivirozo, rinotraheitisom in panlevkopenijo.
The vaccine also contains aluminium hydroxide and extract of Quillaja saponaria as adjuvants (ingredients that strengthen the immune response). 
Cepivo kot dodatka (sestavini, ki spodbudita imunski odziv) vsebuje tudi aluminijev hidroksid in izvleček Quillaja saponaria.
Leucofeligen FeLV/RCP is given to kittens as two injections under the skin. 
Zdravilo Leucofeligen FeLV/RCP se mačjim mladičem injicira pod kožo v dveh odmerkih.
What benefits of Leucofeligen FeLV/RCP have been shown in studies? 
Kakšne koristi je zdravilo Leucofeligen FeLV/RCP izkazalo v študijah?
Protection against leukaemia lasts for 3 years once a booster has been given and lasts for one year for calicivirosis and viral rhinotracheitis. 
Zaščita pred levkemijo traja tri leta po obnovitvenem odmerku, zaščita pred kalicivirozo in virusnim rinotraheitisom pa traja eno leto.
What are the risks associated with Leucofeligen FeLV/RCP? 
Kakšna tveganja so povezana z zdravilom Leucofeligen FeLV/RCP?
Its use is not recommended in cats nursing kittens. 
Prav tako njegova uporaba ni priporočljiva v obdobju laktacije.
Leucofeligen FeLV/RCP received a marketing authorisation valid throughout the EU on <date of issue of the Marketing Authorisation>. 
Zdravilo Leucofeligen FeLV/RCP je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 25. junija 2009.
How is Leucofeligen FeLV/RCP used? 
Kako se zdravilo Leucofeligen FeLV/RCP uporablja?
How does Leucofeligen FeLV/RCP work? 
Kako zdravilo Leucofeligen FeLV/RCP deluje?
Leucofeligen FeLV/RCP is a vaccine used to protect cats from eight weeks of age against the following diseases: feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus); feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus); feline panleucopenia (a serious illness causing bloody diarrhoea and a fall in white blood cell counts caused by a parvovirus); feline leukaemia (an illness affecting the immune system causing loss of appetite, weight loss, poor fur condition, fever, pale gums and diarrhoea caused by a retrovirus). 
levkemiji mačk (bolezni, ki prizadene imunski sistem in povzroča izgubo teka, hujšanje, slabo stanje dlake, povišano telesno temperaturo, blede dlesni in drisko ter jo povzroča retrovirus).
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 
Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikovdovoljenja za promet z zdravilom v državah članicah
Levonorgestrel-containing emergency contraceptive medicinal products Member State (in EEA) 
Za zdravila, ki vsebujejo levonorgestrel in se uporabljajo za nujno kontracepcijo Država članica (v
Czech Republic Gedeon Richter Plc. 
Velika Britanija Gedeon Richter Plc.
Belgium Laboratoire HRA Pharma 15, rue Béranger 
Portugalska Laboratoire HRA Pharma 15, rue Béranger
Supportive data suggested that the benefit was maintained for up to two years. 
Podporni podatki so nakazali, da so se koristi ohranile do dve leti.
The recommended dose is 3 mg for each kg of bodyweight. 
Priporočeni odmerek je 3 mg na vsak kilogram telesne mase.
The infusion should be given once every four weeks, for as long as the patient is considered to benefit, and doctors should re-assess at least once a year whether treatment should be continued. 
Infuzijo je treba dati enkrat na štiri tedne, dokler ima bolnik od tega korist, zdravnik pa naj o nadaljevanju zdravljenja presodi vsaj enkrat letno.
Anaphylactic (severe allergic) reactions may affect less than 1 person in 100. 
Anafilaktične (hude alergijske) reakcije se lahko pojavijo pri manj kot 1 bolniku od 100.
Overall the medicine was well tolerated, and appropriate measures to monitor and manage risks have been put in place. 
V celoti gledano so bolniki zdravilo dobro prenašali, poleg tega so bili uvedeni ustrezni ukrepi za spremljanje in obvladovanje tveganj.
What measures are being taken to ensure the safe and effective use of Cinqaero? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cinqaero?
The full EPAR for Cinqaero can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cinqaero je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Flare-ups were seen in 32% of patients (151 out of 477) given Cinqaero compared with 50% (237 out of 476) of those given placebo. 
Poslabšanja so bila opažena pri 32 % (151 od 477) bolnikov, ki so prejemali zdravilo Cinqaero, in pri 50 % (237 od 476) bolnikov, ki so prejemali placebo.
This is a summary of the European public assessment report (EPAR) for Cinqaero. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cinqaero.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cinqaero večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Other information about Cinqaero 
Druge informacije o zdravilu Cinqaero
This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms. 
S tem pomaga zmanjšati vnetje, kar zmanjša število napadov astme in izboljša simptome.
What are the risks associated with Cinqaero? 
Kakšna tveganja so povezana z zdravilom Cinqaero?
It is not intended to provide practical advice on how to use Cinqaero. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cinqaero have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cinqaero upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The most common side effect with Cinqaero (which may affect about 2 people in 100) is an increase in levels of the enzyme creatine phosphokinase in the blood (a measure of possible damage to muscles). 
Najpogostejši neželeni učinek zdravila Cinqaero (ki se lahko pojavi pri približno 2 bolnikih od 100) je zvečanje vrednosti encima kreatin-fosfokinaze v krvi (merilo možne poškodbe mišic).
What benefits of Cinqaero have been shown in studies? 
Kakšne koristi je zdravilo Cinqaero izkazalo v študijah?
What is Cinqaero and what is it used for? 
Kaj je zdravilo Cinqaero in za kaj se uporablja?
For more information about treatment with Cinqaero, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Cinqaero preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Why is Cinqaero approved? 
Zakaj je bilo zdravilo Cinqaero odobreno?
The main measure of effectiveness was based on the number of flare-ups (exacerbations) of asthma during treatment. 
Glavno merilo učinkovitosti je temeljilo na številu poslabšanj astme pri zdravljenju.
For practical information about using Cinqaero, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Cinqaero naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Cinqaero, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Cinqaero glejte navodilo za uporabo.
The benefits of Cinqaero have been shown in two main studies involving 953 patients with eosinophilic asthma that was not well controlled by inhaled corticosteroids and other asthma medication used for the prevention of the disease. 
Koristi zdravila Cinqaero so bile dokazane v dveh glavnih študijah, ki sta vključevali 953 bolnikov z eozinofilno astmo, ki ni bila urejena z inhalacijskimi kortikosteroidi in drugim zdravilom za preprečevanje astme.
It is used as an additional treatment in adults with severe asthma that is not properly controlled by a combination of high-dose corticosteroids taken by inhalation plus another medicine used for the prevention of asthma. 
Uporablja se kot dodatno zdravljenje pri odraslih s hudo astmo, ki ni ustrezno urejena s kombinacijo visokih odmerkov inhalacijskih kortikosteroidov in drugega zdravila za preprečevanje astme.
It is available as a concentrate for making a solution for infusion (drip) into a vein. 
Zdravilo je na voljo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Cinqaero is an asthma medicine that is used to treat adults with a particular type of asthma called eosinophilic asthma. 
Cinqaero je zdravilo za astmo, ki se uporablja za zdravljenje odraslih s posebno vrsto astme, imenovano eozinofilna astma.
The reduction in flare-ups and improvement in lung function seen with Cinqaero were considered clinically relevant, particularly for patients who cannot be adequately controlled with high doses of inhaled corticosteroids and another medicine used for the prevention of asthma. 
Zmanjšanje poslabšanj astme in izboljšanje pljučne funkcije pri jemanju zdravila Cinqaero sta bila ovrednotena kot klinično pomembna, zlasti za bolnike, pri katerih astme ni mogoče zadovoljivo urediti z visokimi odmerki inhalacijskih kortikosteroidov in drugim zdravilom za preprečevanje astme.
By attaching to interleukin-5 and blocking its activity, Cinquaero reduces the number of eosinophils in the blood and lungs. 
Z vezavo na interlevkin-5 in blokiranjem njegovega delovanja zdravilo Cinqaero zmanjša
The medicine contains the active substance reslizumab. 
Zdravilo Cinqaero vsebuje zdravilno učinkovino reslizumab.
Cinqaero can only be obtained with a prescription and should be prescribed by doctors with experience in the treatment of eosinophilic asthma. 
Predpisovanje in izdaja zdravila Cinqaero je le na recept, zdravilo pa mora predpisati zdravnik, ki ima izkušnje z zdravljenjem eozinofilne astme.
How does Cinqaero work? 
Kako zdravilo Cinqaero deluje?
Additionally there was evidence of an improvement in lung function and asthma symptoms, and a decrease in number of eosinophils in the blood in patients given Cinqaero. 
Poleg tega je pri bolnikih, zdravljenih z zdravilom Cinqaero, prišlo do izboljšanja pljučne funkcije in simptomov astme ter zmanjšanja števila eozinofilcev v krvi.
The active substance in Cinqaero, reslizumab, is a monoclonal antibody designed to attach to a substance called interleukin-5, which 
Zdravilna učinkovina v zdravilu Cinqaero, reslizumab, je monoklonsko protitelo, zasnovano za vezavo na interlevkin-5, tj. snov, ki stimulira rast in aktivnost eozinofilcev.
How is Cinqaero used? 
Kako se zdravilo Cinqaero uporablja?
Cinqaero was compared with placebo (a dummy infusion), both given every 4 weeks for a year. 
Zdravilo Cinqaero so primerjali s placebom (infuzijo brez zdravilne učinkovine).
An appropriate positive control was used. 
Uporabljena je bila primerna pozitivna kontrola.
The response was submitted to the EMEA on 23 March 2006. 
Odgovor je bil 23. marca 2006 posredovan EMEA.
The result of the test was negative. 
Rezultat analize je bil negativen.
The reason for this was that the United Kingdom national competent authority, Veterinary Medicines Directorate (VMD) considered that this medicinal product could present a potential serious risk to public health on the following grounds: 
Pristojni nacionalni organ Združenega kraljestva, Direktorat za veterinarska zdravila (VMD), je bil namreč mnenja, da lahko to zdravilo predstavlja potencialno veliko tveganje za javno zdravje, in sicer na podlagi:
The product is indicated to treat respiratory diseases in horses caused by Streptococcus equi subsp. 
Izdelek je namenjen zdravljenju bolezni dihal pri konjih, ki jih povzroča Streptococcus equi subsp.
One positive result on chromosome aberration was reported. 
Poročali so o enem pozitivnem rezultatu kromosomske aberacije.
Pursuant to Article 33(4) of Directive 2001/82/EC, as amended, the matter has been referred to the CVMP. 
Skladno s členom 33(4) Direktive 2001/82/ES, kakor je bila spremenjena, je bila zadeva napotena na CVMP.
ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER 
DODATEK I IME, FARMACEVTSKA OBLIKA, JAKOST ZDRAVIL, ŽIVALSKE VRSTE, NAČINI UPORABE ZDRAVILA IN IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
Therefore it can be concluded that the effect seen in vitro is not of biological relevance. 
Tako je mogoče zaključiti, da učinek, viden in vitro, ni biološko pomemben.
Therefore, the Committee considered that no further mutagenicity study is required for the assessment of the substance. 
Zato je Odbor mnenja, da za oceno snovi dodatne raziskave mutagenosti niso potrebne.
zooepidemicus and severe bacterial infections with a high risk of septicaemia in foals in which Escherichia coli is involved. 
zooepidemicus, in hudih bakterijskih okužb z visokim tveganjem septikemije pri žrebcih, kjer je vpletena tudi Escherichia coli.
Taking into account the intrinsic values and limitations of the tests and that only one out of eleven studies has shown positive results, it is concluded that there are no concerns that 2,3-cyclohexenopyridine may present a potential serious risk to public health. 
Ob upoštevanju intrinzičnih vrednosti in omejitev analiz in da je le ena od enajstih analiz dala pozitivne rezultate, se zaključi, da ni nevarnosti, da bi 2,3cikloheksenopiridin predstavljal potencialno resno tveganje za javno zdravje.
The Reference Member State for the Mutual Recognition Procedure regarding Cobactan IV 4.5%, Germany, notified the EMEA on 2 March 2006 that the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary (CMD(v)) failed to reach an agreement regarding the product. 
Referenčna država članica za postopek medsebojnega priznavanja zdravila Cobactan IV 4,5 %, Nemčija, je 2. marca 2006 obvestila EMEA, da Koordinacijska skupina za medsebojno priznavanje in decentralizirane postopke - veterina (CMD(v)) ni sklenila dogovora o izdelku.
In conclusion, the CVMP agrees that it was sufficiently demonstrated that 2,3-cyclohexenopyridine has no clastogenic potential in vivo, and that further studies are not warranted. 
CVMP se na koncu strinja, da je bilo zadovoljivo dokazano, da 2,3-cikloheksenopiridin nima klastogenega potenciala in vivo in da nadaljnje raziskave niso upravičene.
Cobactan IV 4.5%, presented as a powder and solvent for solution for injection, contains 45 mg/ml cefquinome (as sulphate). 
Zdravilo Cobactan IV 4,5 % v obliki praška in vehikla za raztopino za injiciranje vsebuje 45 mg/ml cefkvinoma (kot sulfat).
The CVMP during its meeting of 14-16 March 2006 initiated a referral procedure under Article 33(4) of Directive 2001/82/EC, as amended, for Cobactan IV 4.5% containing cefquinome. 
CVMP je na zasedanju 14.-16. marca 2006 sprožil postopek v skladu s členom 33(4) Direktive 2001/82/ES, kakor je bila spremenjena, za zdravilo Cobactan IV 4,5 %, ki vsebuje cefkvinom.
Cobactan Powder and solvent for solution for injection 
Cobactan Prašek in vehikel za raztopino za injiciranje
The highest dose corresponded to the maximum tolerated in a dose range finding assay and also caused clear symptoms of toxicity but no lethality in all animals of the main study. 
Najvišji odmerek je ustrezal največji vrednosti, ki je še sprejemljiva v analizi iskanja razpona odmerka, in je pri vseh živalih glavne raziskave povzročil jasne simptome toksičnosti, vendar ne smrtnosti.
The positive finding in vitro was further investigated in an in vivo micronucleus test. 
Pozitiven izid in vitro je bil nadaljnje raziskan z in vivo analizo mikronukleusa.
Given (1) the high proliferation rate of bone marrow tissue, (2) the intravenous route of administration, and (3) the high doses employed, it is highly unlikely that a second in vivo test in another tissue would give a positive result. 
Glede na (1) hitro proliferacijo celic kostnega mozga, (2) intravensko odmerjanje zdravila, in (3) velike odmerke, je zelo malo verjetno, da bi druga in vivo analiza v drugem tkivu dal pozitiven rezultat.
Genotoxicity testing was carried out at the impurity concentration of 1% with cefquinome (8 tests) and in addition 3 tests have been carried out with 2,3-cyclohexenopyridine alone. 
Opravljena je bilo genotoksična analiza cefkvinoma pri 1 % koncentraciji nečistoče (8 analiz), poleg tega so bile opravljene še 3 analize z 2,3-cikloheksenopiridinom samim.
Despite the fact that there have also been negative results in two in vivo micronucleus assays, the positive in vitro results are not negated, as both in vivo studies involved the assessment of effects in bone marrow cells. 
Kljub temu, da so bili rezultati v dveh in vivo analizah mikronukleusa negativni, pozitivni in vitro rezultati niso izničeni, saj sta obe in vivo raziskavi vključevali oceno vpliva na celice kostnega mozga.
The questions identified related to the concerns raised regarding the potential mutagenicity of 2,3cyclohexenopyridine, the starting material and impurity of cefquinome and were submitted to the Marketing Authorisation Holder on 16 March 2006. 
Vprašanja o zaskrbljenosti glede potencialne mutagenosti 2,3-cikloheksenopiridina, o vhodni snovi in nečistosti cefkvinoma, so bila 16. marca 2006 predložena imetniku dovoljenja za promet z zdravilom.